SK Bioscience Vaccine Factory Andong L House▶ Click here for a larger view
Individual investors who bought SK Bioscience’s stock price at the peak after walking downhill day after day after the listing date are sad.
According to the Korea Exchange on the 27th, in the stock market on the 26th, SK Biosciences finished trading at 132,000 won, down 2.94% from the previous trading day.
SK Bioscience, which has been selected as a major IPO in the first half of this year, has achieved a record-breaking sales of 63 trillion won in margin.
Following the enthusiasm for subscription, the initial price on the date of listing was doubled that of the public offering price, and it entered the stock market as a so-called’dasang’ that soared to the upper limit.
However, from the 19th, the second day of listing, the stock price fell for six consecutive trading days. During this period, the stock price fell by 21.89%, approaching 130,000 won at the beginning of the listing date.
In the meantime, individual investors steadily bought SK Bioscience.
On the first day of listing, individuals net bought 29.8 billion won worth of 169,000 won. In addition, the company closed down 1.48%, but net purchase of 167 billion won the day after listing, when the closing price remained in the 160,000 won range.
In particular, on the second day of listing, the stock price rose to 190,000 won during the day.
In this way, in the first two days of listing, the net purchase amount of SK Bioscience by individuals amounted to 197.7 billion won.
For two days, the ants received net sales worth 136.3 billion won and 43 billion won, respectively, at the peak of foreigners and institutions.
However, the stock price of SK Bioscience plunged 13.51% on the 3rd day of listing and fell to 140,000 won, then continued to decline and fell to 132,000 won on the 26th.
During this period, individuals continued to have an advantage in buying, except on the 24th, which showed a slight (3.9 billion won) selling advantage. After listing, the net purchase amount for 7 trading days totaled 235.9 billion won.
It can be estimated that there are a large number of individual investors who are buying SK Bioscience at its peak.
However, the stock price is still more than double the offering price of 65,000 won, so investors who have received the offer for offering stock are making profits.
Like SK Bioscience, the phenomenon of a large number of individual investors in the early stages of listing of popular public offering stocks is recurring.
Looking at individual net purchases during the initial 7 trading days of listing, SK Biopharm is 582.3 billion won, Kakao Games 3722 billion won, and Big Hit 463.7 billion won.
However, both of these stocks surged immediately after listing and turned to a downtrend, and have yet to recover to the initial level of listing.
[연합뉴스]
Copyrights ⓒ Yonhap News. Unauthorized reproduction and redistribution prohibited